Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
Find out more about us
26 April 2022
13 April 2022
11 April 2022
16 March 2022
Find out more
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies in 2022
Sareum has an innovative pipeline of drug development candidates.
BioTrinity, April 2022 (Slides)IMC Half Year Results, Feb 2022 (Slides)IMC Full Year Results, Oct 2021 (Slides)LSX World Congress, Feb 2021 (Video)
Share price dataRegulatory News Service (RNS)
Sareum LimitedUnit 2A, Langford ArchLondon Road, PampisfordCambridge CB22 3FXUnited Kingdom
tel: +44 (0) 1223 497700fax: +44 (0) 1223 497701
Full-year Results 2021 ¦ Brochure Jan 2021
Annual Report 2021 ¦